Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
Sign Up to like & getrecommendations! Published in 2021 at "OncoTargets and therapy"
DOI: 10.2147/ott.s272208
Abstract: Abstract Cholangiocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of 11–44% after surgical resection. However, there is no established systemic therapy after failure of the gemcitabine plus cisplatin first-line therapy… read more here.
Keywords: cholangiocarcinoma; therapy advanced; genomic aberrations; advanced cholangiocarcinoma ... See more keywords